Epitalon is the pineal AEDG tetrapeptide claimed to switch telomerase back on — here is what the studies actually measured.

The short version

Epitalon is a tiny lab-made peptide — a chain of just four amino acids, written Ala-Glu-Asp-Gly, or AEDG for short (a tetrapeptide is simply a peptide built from four building blocks). It was modeled on epithalamin, an older preparation extracted from the pineal gland, a pea-sized organ in the brain that makes the sleep hormone melatonin. Researchers have studied Epitalon mainly for one bold idea: that it can switch on telomerase (the enzyme that rebuilds the protective caps on the ends of your chromosomes) and, through that, slow aging. In animals and in cells, studies report longer lifespan, restored telomere length, and steadier day-night rhythms. But here is the honest catch: almost all of that work came from a single Russian group, the human data was never a proper randomized trial, and the headline anti-aging promises have not been confirmed by independent human research. Epitalon is investigational — not an approved drug and not a dietary supplement. What people report — including the people who felt nothing — is on the effects page.

What the Epitalon literature has demonstrated — and where it stops

Across roughly three decades of work, Epitalon has produced a striking and internally consistent record in cells and animals. Added to human fetal fibroblast cultures that had no telomerase activity, the peptide induced expression of the catalytic telomerase subunit hTERT, restored telomerase activity, and lengthened telomeres ^[1]. In female SHR mice dosed at 1.0 μg per mouse subcutaneously for five days a month, maximum lifespan rose 12.3% and leukemia fell six-fold, with no rise in total tumor incidence ^[3]. In fruit flies, lifespan increased 11-16% ^[7].

The ceiling is the human evidence. The most-cited human result is a 6-8 year observational follow-up of 266 elderly people, which reported lower mortality in those given the pineal peptide — but it was not randomized and had no placebo arm by Western standards ^[2]. There are no Phase II or III randomized controlled trials registered for Epitalon. So the pattern of this page, and this site, is fixed: the preclinical findings are presented as findings, and the lifespan-and-anti-aging claims are presented as claims — because in rigorous, independently replicated human trials, they have not been demonstrated.

One laboratory, one lineage — the caveat that frames everything

The single most important fact about Epitalon is not a mechanism. It is an attribution. The foundational studies — the human-cell telomerase result, the mouse lifespan data, the fly data, the human cohort — come overwhelmingly from Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology ^[1]. For two decades, independent non-Russian replication of the core telomere claim was sparse. That changed only recently: a 2025 study from a separate group confirmed that Epitalon lengthens telomeres in normal human cells via hTERT, while finding that in breast-cancer cell lines the lengthening ran through a different route called Alternative Lengthening of Telomeres ^[5]. One independent replication is a beginning, not a verdict. The reader should treat a body of evidence that flows from a single source with the caution that single-source evidence always deserves — which is exactly what this digest tries to model. The longer treatment is on epitalon longevity.

A distinction worth getting right: Epitalon is not epithalamin

Epitalon and epithalamin are constantly conflated, including in marketing copy, and the difference matters. Epithalamin is the parent preparation — a polypeptide extract of the bovine pineal gland, a mixture, used in the older Russian clinical work. Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, designed to represent the active sequence drawn from that extract. They are chemically distinct and legally distinct, and their evidence bases should not be pooled as if one molecule ^[4]. (The spelling Epithalon, with an h, refers to the same synthetic molecule as Epitalon; this site uses the spelling Epitalon throughout.) One more clarification belongs here: Epitalon is not a dietary supplement and not an approved medicine. It is a research chemical with no FDA, EMA, or MHRA approval for any human use ^[4]. The full reading of the benefits-versus-evidence question lives on epitalon benefits.

How to read this site

This is an editorial digest, not a clinic and not a store. The Epitalon research page lays out the proposed mechanisms — telomerase, the melatonin axis, the chromatin hypothesis — study by study. The longevity page takes the geroprotector claim apart and foregrounds the single-lab caveat. The benefits page separates what is claimed from what is shown. The effects page collects what the research-use community reports, clearly labeled as anecdote, alongside cited safety cautions. The Epitalon references page lists every source with its DOI or PubMed link. Nothing here is a dose recommendation, a treatment plan, or medical advice; the dosage page describes only what was administered to which species, by which route, in published studies.